Replies to post #78629 on Biotech Values

[bridgeofsighs]

>>portion of that post you are stunned about
It seems that this meaningless FDA approval of a next generation DES from BSX has ignited a new interest in the drug eluting stent business. The people pumping ANPI are making this approval as some kind of revolution in the DES space and it is completely meaningless. The most stunning part was calling current DES as obsolete and the fact that STJ does not have a DES on the market. The $10 share price just is not gonna happen in actuality ANPI could be a dead company walking.